CN115073583A - 识别hla-cw8限制性突变kras的t细胞受体 - Google Patents

识别hla-cw8限制性突变kras的t细胞受体 Download PDF

Info

Publication number
CN115073583A
CN115073583A CN202111083392.9A CN202111083392A CN115073583A CN 115073583 A CN115073583 A CN 115073583A CN 202111083392 A CN202111083392 A CN 202111083392A CN 115073583 A CN115073583 A CN 115073583A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
leu
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111083392.9A
Other languages
English (en)
Chinese (zh)
Inventor
埃里克·特兰
卢勇成
史蒂文·A·罗森伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of CN115073583A publication Critical patent/CN115073583A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
CN202111083392.9A 2015-09-15 2016-09-09 识别hla-cw8限制性突变kras的t细胞受体 Pending CN115073583A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562218688P 2015-09-15 2015-09-15
US62/218,688 2015-09-15
CN201680058891.3A CN108350059B (zh) 2015-09-15 2016-09-09 识别hla-cw8限制性突变kras的t细胞受体
PCT/US2016/050875 WO2017048593A1 (en) 2015-09-15 2016-09-09 T cell receptors recognizing hla-cw8 restricted mutated kras

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680058891.3A Division CN108350059B (zh) 2015-09-15 2016-09-09 识别hla-cw8限制性突变kras的t细胞受体

Publications (1)

Publication Number Publication Date
CN115073583A true CN115073583A (zh) 2022-09-20

Family

ID=56985686

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202111083392.9A Pending CN115073583A (zh) 2015-09-15 2016-09-09 识别hla-cw8限制性突变kras的t细胞受体
CN201680058891.3A Active CN108350059B (zh) 2015-09-15 2016-09-09 识别hla-cw8限制性突变kras的t细胞受体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680058891.3A Active CN108350059B (zh) 2015-09-15 2016-09-09 识别hla-cw8限制性突变kras的t细胞受体

Country Status (13)

Country Link
US (3) US10556940B2 (https=)
EP (2) EP3901169B1 (https=)
JP (2) JP7185524B2 (https=)
KR (2) KR20250117744A (https=)
CN (2) CN115073583A (https=)
AU (3) AU2016323017B2 (https=)
DK (1) DK3350213T3 (https=)
ES (1) ES2879287T3 (https=)
IL (1) IL257840B2 (https=)
MX (1) MX2018003062A (https=)
SA (1) SA518391109B1 (https=)
SG (1) SG10201913868XA (https=)
WO (1) WO2017048593A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2592821B (en) 2015-07-31 2022-01-12 Univ Minnesota Modified cells and methods of therapy
WO2018026691A1 (en) * 2016-08-02 2018-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-kras-g12d t cell receptors
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
WO2018183485A1 (en) * 2017-03-31 2018-10-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating neoantigen-specific t cell receptor sequences
US11807662B2 (en) 2017-05-16 2023-11-07 The Johns Hopkins University MANAbodies and methods of using
WO2019006418A2 (en) 2017-06-30 2019-01-03 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
EP3684799A1 (en) 2017-09-20 2020-07-29 The U.S.A. as represented by the Secretary, Department of Health and Human Services Hla class ii restricted t cell receptors against mutated ras
AU2018345400B2 (en) 2017-10-05 2024-06-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for selectively expanding cells expressing a TCR with a murine constant region
EP3720478A1 (en) * 2017-12-04 2020-10-14 The United States of America, as represented by the Secretary, Department of Health and Human Services Hla class i-restricted t cell receptors against mutated ras
BR112020025764A2 (pt) * 2018-06-19 2021-05-11 Biontech Us Inc. neoantígenos e usos dos mesmos
CN112888707B (zh) 2018-08-16 2025-04-25 百欧恩泰美国公司 T细胞受体构建体及其用途
CN113412277B (zh) * 2019-01-22 2025-07-18 美国卫生和人力服务部 针对含有g12r突变的ras的hla第ii类限制性t细胞受体
WO2020172332A1 (en) 2019-02-20 2020-08-27 Fred Hutchinson Cancer Research Center Binding proteins specific for ras neoantigens and uses thereof
US20220175899A1 (en) * 2019-04-11 2022-06-09 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer
CN110172089B (zh) * 2019-06-11 2020-01-07 北京鼎成肽源生物技术有限公司 一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用
CN112110995A (zh) * 2019-06-19 2020-12-22 上海交通大学医学院 肿瘤新抗原多肽及其用途
WO2021029046A1 (ja) * 2019-08-14 2021-02-18 日本電気株式会社 情報処理装置、情報処理方法及び記録媒体
CN112759641B (zh) * 2019-11-01 2023-01-20 香雪生命科学技术（广东）有限公司 一种识别Kras G12V的高亲和力TCR
WO2021123832A1 (en) 2019-12-20 2021-06-24 Instil Bio (Uk) Limited Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
AU2021220957A1 (en) * 2020-02-14 2022-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HLA class I-restricted T cell receptors against ras with G12V mutation
CN111574616B (zh) * 2020-06-17 2021-02-02 深圳豪石生物科技有限公司 分离的t细胞受体和应用
CN116348484A (zh) * 2020-07-16 2023-06-27 美国卫生和人力服务部 针对含有g12v突变的ras的hla-ii类限制性drb t细胞受体
TW202540156A (zh) * 2020-10-02 2025-10-16 美國衛生與公眾服務部 針對含有g13d突變之ras之hla第ii類限制性dq t細胞受體
IL305393A (en) 2021-02-25 2023-10-01 Alaunos Therapeutics Inc Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
US20250145950A1 (en) 2022-02-01 2025-05-08 Alaunos Therapeutics, Inc. Methods for Activation and Expansion of T Cells
CN114920824B (zh) * 2022-05-27 2023-12-05 重庆医科大学 Tcr或其抗原结合片段及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050037455A1 (en) * 2002-05-30 2005-02-17 Kolesnick Richard N. Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis
CN103249430A (zh) * 2010-09-20 2013-08-14 生物技术公司 抗原特异性t细胞受体和t细胞表位
CN103974974A (zh) * 2011-09-15 2014-08-06 美国卫生和人力服务部 识别hla-a1-或hla-cw7-限制的mage的t细胞受体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003265948B8 (en) 2002-09-06 2009-09-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
WO2007017201A1 (en) * 2005-08-05 2007-02-15 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh Generation of antigen specific t cells
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
GB201314404D0 (en) * 2013-08-12 2013-09-25 Immunocore Ltd T Cell Receptors
MX384919B (es) * 2014-11-26 2025-03-14 Us Health Receptores de células t de kras anti-mutado.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050037455A1 (en) * 2002-05-30 2005-02-17 Kolesnick Richard N. Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis
CN103249430A (zh) * 2010-09-20 2013-08-14 生物技术公司 抗原特异性t细胞受体和t细胞表位
CN103974974A (zh) * 2011-09-15 2014-08-06 美国卫生和人力服务部 识别hla-a1-或hla-cw7-限制的mage的t细胞受体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FREDERICK D. TSAI ET AL.: "K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif", PNAS, vol. 112, no. 3, 20 January 2015 (2015-01-20), pages 779 - 784, XP055314164, DOI: 10.1073/pnas.1412811112 *

Also Published As

Publication number Publication date
AU2021200833B2 (en) 2022-04-28
US10556940B2 (en) 2020-02-11
AU2016323017B2 (en) 2020-11-12
ES2879287T3 (es) 2021-11-22
CN108350059B (zh) 2021-10-08
AU2021200833A1 (en) 2021-03-04
JP7461445B2 (ja) 2024-04-03
JP7185524B2 (ja) 2022-12-07
AU2022209229A1 (en) 2022-09-15
EP3901169B1 (en) 2026-01-28
EP3350213B1 (en) 2021-03-31
SA518391109B1 (ar) 2022-02-14
KR20180044428A (ko) 2018-05-02
US20190040111A1 (en) 2019-02-07
CA2998869A1 (en) 2017-03-23
SG10201913868XA (en) 2020-03-30
WO2017048593A1 (en) 2017-03-23
AU2022209229B2 (en) 2024-05-23
CN108350059A (zh) 2018-07-31
AU2016323017A1 (en) 2018-04-05
DK3350213T3 (da) 2021-06-21
US20230406904A1 (en) 2023-12-21
IL257840B1 (en) 2023-06-01
HK1257902A1 (en) 2019-11-01
JP2018535647A (ja) 2018-12-06
EP3901169A1 (en) 2021-10-27
KR20250117744A (ko) 2025-08-05
EP3350213A1 (en) 2018-07-25
MX2018003062A (es) 2018-09-11
US11667692B2 (en) 2023-06-06
IL257840A (en) 2018-04-30
JP2023025108A (ja) 2023-02-21
US20200148739A1 (en) 2020-05-14
KR102841067B1 (ko) 2025-08-01
IL257840B2 (en) 2023-10-01

Similar Documents

Publication Publication Date Title
US20230406904A1 (en) T cell receptors recognizing hla-cw8 restricted mutated kras
KR102527052B1 (ko) 항-kras-g12d t 세포 수용체
JP7635165B2 (ja) ｐ５３におけるＲ１７５Ｈ又はＹ２２０Ｃ変異を認識するＴ細胞受容体
EP4103597A1 (en) Hla class i-restricted t cell receptors against ras with g12d mutation
EP4441087A1 (en) Hla-a3-restricted t cell receptors against ras with g12v mutation
WO2024097655A1 (en) T cell receptors targeting mutated cdkn2a
KR20230046294A (ko) G12v 돌연변이를 갖는 ras에 대한 hla 클래스 ii-제한된 drb t 세포 수용체
CA2998869C (en) T cell receptors recognizing hla-cw8 restricted mutated kras
US20230312672A1 (en) Hla class i-restricted t cell receptors against cd20
WO2022225836A1 (en) Hla class i-restricted t cell receptors against ras with q61k mutation
HK1257902B (en) T cell receptors recognizing hla-cw8 restricted mutated kras
WO2022177961A1 (en) Hla class i–restricted t cell receptors against cd22
EA045621B1 (ru) T-клеточные рецепторы, рестриктированные по антигену лейкоцитов человека класса ii, против мутантного ras

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination